Gerald Lushington

Collaborative Computational Scientist

In a 26-year career, Dr. Gerald Lushington has collaborated on diverse research in drug discovery, molecular biology, chemical synthesis, data mining, and other fields. He has directly supported 29 funded projects in roles ranging from principal investigator, core lead to consultant. Various federal agencies such as the NIH and DOD have supported Lushington's work.

Lushington's research has produced five patents, and more than 200 peer-reviewed papers, leading to more than 5700 citations. Serving on multiple external advisory boards, He serves as Editor in Chief for informatics in the journal Combinatorial Chemistry & High Throughput Screening, and sits on editorial boards of The Open Enzyme Inhibition Journal, Current Bioactive Compounds, and the Journal of Clinical Bioinformatics. He has reviewed proposals for the U.S. Civilian Research and Development Foundation, the U.S. Defense Threat Reduction Agency, and the Czech Science Foundation.

Informatician, Entrepreneur and Consultant

Lushington is currently Head of Data Science at Progentec Diagnostics, Inc. He is also Chief Scientific Officer and co-founder of Qnapsyn Biosciences, Inc., which is an early-stage startup focusing on a novel target class for development of immunometabolic and neurological diagnostics and biologics. He also remains an active consultant, having developed and applied a diverse array of analytical technologies in support of scientists, and secured and administered consulting projects with multiple corporations, including the Rajiv Ghandi Centre for Biotechnology, Cydex Pharmaceuticals, Inc., Sidley Austin, LLP, and Vanda Pharmaceuticals, Inc.